A PYMNTS Company

EU OKs Merger Of Pfizer Off-Patent Unit And Mylan

By  |  April 22, 2020

The European Commission on Wednesday, April 22, authorized a merger of US drug giant Pfizer’s off-patent business unit with the pharmaceutical company Mylan to create a global powerhouse for lower-cost medicines.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The merger between Pfizer’s Upjohn unit, based in China, and Netherlands-based Mylan will create a new company selling popular products such Viagra, the anti-cholesterol drug Lipitor, and the anti-allergy injector EpiPen.

    But it is conditional on Mylan divesting certain generic medicines, the Commission said in a statement.

    Once effected, it would ensure the merger “does not harm competition, thus preserving competitive access to certain genericised medicines for national health services and European citizens,” EU competition commissioner Margrethe Vestager said.

    Mylan and Upjohn overlap in cardiovascular, genito-urinary, musculoskeletal, nervous system, and sensory organ treatments areas, but “no competition concerns arise for the majority of the products” both companies put out, the Commission stated.

    Full Content: Medical Xpress

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.